23:49 , Jun 6, 2019 |  BC Extra  |  Company News

Management tracks: Grail taps Juno founder Bishop as CEO; plus Clovis, OncoCyte, Calico

Grail Inc. (Menlo Park, Calif.) hired Hans Bishop as CEO to succeed Jennifer Cook, who also stepped down from the cancer diagnostic company's board, citing family health reasons. Bishop, who has been on Grail’s board...
03:03 , Feb 15, 2019 |  BC Innovations  |  Tools & Techniques

Heartening predictors in diabetes

New biomarkers of cardiovascular risk could relieve a decade-old bottleneck for diabetes drug development, but validating them will require companies to invest in strategic trial designs, and public and private stakeholders to pool thinking. As...
05:09 , Jan 5, 2019 |  BioCentury  |  Product Development

Bristol-Myers’ next phoenix act?

Bristol-Myers Squibb Co. will now be in the driver’s seat to monetize the assets gained from the myriad deals Celgene Corp. has forged. The pharma will need to mimic its history of using well-timed acquisitions...
01:21 , Dec 8, 2018 |  BioCentury  |  Strategy

Novo gets serious about AI-guided drug design

Novo Nordisk A/S is fashioning its R&D makeover to integrate artificial intelligence across its drug discovery and development process, after a pilot program delivered the cost and time savings the pharma was looking for. In...
02:10 , Oct 20, 2018 |  BioCentury  |  Product Development

CVOT damage in diabetes

As FDA reconsiders its requirement for cardiovascular outcomes trials of new diabetes candidates, it’s clear that the development of new therapies has slowed since it was implemented. In December 2008, FDA issued guidance requiring diabetes...
19:58 , Sep 21, 2017 |  BC Innovations  |  Targets & Mechanisms

Appetite for GFRAL

Simultaneous publications from Eli Lilly and Co ., Johnson & Johnson and Novo Nordisk A/S identifying GFRAL as the receptor of the anti-obesity hormone GDF15 will undoubtedly accelerate therapeutic translation of the pathway. The race...
19:39 , Jun 23, 2017 |  BC Week In Review  |  Company News

KeyBioscience grants Lilly rights to Type II diabetes platform

The KeyBioscience AG subsidiary of Nordic Bioscience A/S (Herlev, Denmark) granted Eli Lilly and Co. (NYSE:LLY) worldwide rights to develop and commercialize its Dual Amylin Calcitonin Receptor Agonist (DACRA) platform to develop compounds to treat...
00:05 , May 20, 2017 |  BioCentury  |  Strategy

Henri: N of 1

Gaucher’s disease had swollen Brian Berman’s spleen to the size of a basketball and physicians at NIH told the three-year-old’s parents that it had to be removed. It was 1984, there was no effective treatment...
00:41 , Mar 25, 2017 |  BioCentury  |  Strategy

Mountain climbing

U.S. pricing pressure on insulin and hemophilia products have caused Novo Nordisk A/S to guide for negative sales and operating profit growth for the first time ever. While newly launched diabetes and obesity products are...
00:49 , Mar 8, 2017 |  BC Extra  |  Company News

Management tracks

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) said Chairman Leonard Bell will retire from its board, effective May 10. Fosun Kite Biotechnology Co. Ltd., a JV between Kite Pharma Inc. (NASDAQ:KITE) and Shanghai Fosun Pharmaceutical Group Co. Ltd....